<DOC>
	<DOCNO>NCT00429247</DOCNO>
	<brief_summary>Epithelial tumor cell detect bone marrow and/or peripheral blood [ disseminate circulate tumor cell , ( DTCs ) ( CTCs ) respectively ] otherwise metastases-free patient early breast cancer . Several study show presence cell independent factor associate increase incidence early disease relapse disease-related death . In almost 50 % patient , adjuvant chemotherapy eliminate occult tumor cell also associate high probability early relapse death . In 60-70 % patient , DTCs and/or CTCs express HER2/c-neu molecule one two administration monoclonal antibody trastuzumab ( HERCEPTIN ) could eliminate cell period range 3-12 month .</brief_summary>
	<brief_title>Randomized Trial With Trastuzumab Versus Observation Breast Cancer Patients</brief_title>
	<detailed_description>This pilot trial compare efficacy anti-HER2/erb-B2 monoclonal antibody trastuzumab ( HERCEPTIN ) give completion standard adjuvant chemotherapy radiotherapy versus observation patient stage I-III operable breast cancer detectable cytokeratin-19 ( CK-19 ) mRNA-positive tumor cell bone marrow peripheral blood and/or adjuvant treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Age &gt; = 18 year . Performance status ( World Health Organization [ WHO ] ) &lt; 3 Adequate bone marrow function ( absolute neutrophil count &gt; 1000/mm^3 , platelet count &gt; 100000/mm^3 , hemoglobin &gt; 9 gr/mm^3 ) Adequate liver ( bilirubin &lt; 1.5 time upper limit normal SGOT/SGPT &lt; 2 time upper limit normal ) renal function ( creatinine &lt; 2 mg/dl ) Adequate cardiac function ( left ventricular ejection fraction [ LVEF ] &gt; 50 % ) . Informed consent Histologically cytologically confirm breast adenocarcinoma Prior surgical excision primary breast tumor Prior completion standard adjuvant chemotherapy and/or radiotherapy Locally advance disease completion neoadjuvant chemotherapy , surgical excision radiotherapy provide evidence local metastatic disease Absence clinical laboratory evidence metastatic disease Detection CTCs and/or DTCs ( could feasible ) initiation and/or completion adjuvant chemotherapy and/or radiotherapy Expression HER2/cneu primary tumor mandatory Other invasive malignancy within past 5 year except nonmelanoma skin cancer Other concurrent uncontrolled illness Psychiatric illness social situation would preclude study compliance Pregnant nursing Positive pregnancy test History allergic reaction attribute trastuzumab ( HERCEPTIN )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Occult tumor cell</keyword>
	<keyword>Micrometastatic cell</keyword>
	<keyword>Cytokeratin-19</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Completion Adjuvant Treatment</keyword>
</DOC>